Shots:

• Medtronic initiates global pivotal study evaluating its EV ICD system to treat dangerously fast heart rhythms in 400 patients at 60 sites across North America- Europe- the Middle East- Asia- Australia and New Zealand with the 1EPs as defibrillation testing success rate at the implant
• The EV ICD pivotal study follows the chronic EV ICD pilot study- evaluated 21 patients in New Zealand and Australia and early research and acute feasibility studies including the ASD- SPACE & ASD2
• The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional- transvenous ICDs- but with a lead (thin wire) placed outside the heart and veins

Click here to­ read full press release/ article | Ref: Medtronics | Image: Waterfall City